schizophrenia

by University of California, San Francisco edited by Gaby Clark, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Credit: Boris Ivas from Pexels Cameras that have been installed in their homes by the CIA, voices that whisper vicious words, and demons that appear in their bedroom at night. These are the delusions and hallucinations […]

by Elsevier edited by Sadie Harley, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Credit: Pavel Danilyuk from Pexels Researchers have identified a promising new speech biomarker that could significantly enrich clinical trials by reducing sample size requirements and enhancing statistical outcomes. By using speech latency, participants who are likely to show a high

by Ingrid Fadelli, Medical Xpress edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Neurocognitive profiles distinguish between SCZ and HCS. Credit: Chen et al. (Nature Mental Health, 2026). Schizophrenia is a severe and often highly debilitating psychiatric disorder characterized by distorted emotions, thinking patterns and altered perceptions of reality, as

by University of Geneva edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Illustrative image of the connectivity between the cerebellum and the VTA. Credit: Thomas Bolton Apathy, social withdrawal, and loss of motivation—the so-called ”negative” symptoms of schizophrenia—are among the most disabling and hardest to treat. A team from the

by Patrick O’Brien, King’s College London edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes Credit: Unsplash/CC0 Public Domain New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has provided the first direct evidence that schizophrenia is associated with a greater release of serotonin in the frontal cortex, and demonstrates its

Peer-Reviewed Publication The University of Hong Kong image: A research team led by Dr Brian Chung Hon-yin (third left) has revealed that individuals who experienced childhood maltreatment face markedly elevated mental health risks. view more  Credit: The University of Hong Kong A research team led by the Department of Paediatrics and Adolescent Medicine, School of Clinical

by Sanjukta Mondal, Medical Xpress edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Semaglutide significantly improved glycemic control and weight outcomes in individuals with schizophrenia spectrum disorders. Credit: pxhere.com/en/photo/1375343 Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA

About The Study: The results of this randomized clinical trial show that adjunctive semaglutide significantly improved glycemic control and weight outcomes in individuals with schizophrenia spectrum disorders. Secondary outcomes were exploratory. These findings support the use of glucagon-like peptide–1 receptor agonists (GLP-1RAs) as a potential early intervention strategy to reduce cardiometabolic risk in this vulnerable population.